cloprostenol and Ovarian-Cysts

Resumption of ovulatory activity and the timely lysis of the first CL postpartum (pp) are important determinants for the reproductive performance of dairy cows. Cystic ovarian follicles (COFs) and persistent CLs preclude normal ovarian cyclicity and increase the calving interval. The objective of this study was to investigate the effect of GnRH on the incidence of COFs and the effect of PGF2α on the incidence of a prolonged luteal phase (PLP) and on fertility parameters in dairy cows. A total of 476 cows were examined ultrasonographically for the presence of a dominant follicle (12-25 mm, without CL >10 mm; n = 237) or a functional CL (≥20 mm; n = 239) between 28 and 35 days pp and were allocated to one of four groups. Cows with a dominant follicle received 10-μg GnRH (buserelin; group F-T; n = 118) or saline (group F-C; n = 119), and cows with a functional CL received 0.5 mg of a PGF2α analogue (cloprostenol; group CL-T; n = 119) or saline (group CL-C; n = 120) on the day of initial examination, defined as Day 0. Cows were reexamined 7 and 21 days (F-T and F-C) and 3 and 24 days (CL-T and CL-C) later, and COFs were treated immediately after diagnosis in all cows. On the basis of the ovarian findings on Days 21 and 24, cows were treated according to a protocol aimed at timely breeding. The incidence of COFs by Days 7 (F-T vs. F-C; 7.6% vs. 16.8%) and 21 (11.0% vs. 21.8%) decreased (P ≤ 0.03) with GnRH; however, this did not lead to a substantial improvement of calving-to-conception interval (means ± standard error of the mean; 107.91 ± 5.70 vs. 117.94 ± 6.63 days), first-service conception rate (42.3% vs. 41.3%), and number of services per conception (2.06 ± 0.12 vs. 2.31 ± 0.15). Treatment with PGF2α decreased (P < 0.0001) the incidence of PLP by Day 24 (CL-T vs. CL-C; 1.7% vs. 17.5%), decreased calving-to-conception interval(91.28 ± 4.77 vs. 101.75 ± 5.03 days), increased first-service conception rate (63.3% vs. 38.7%), and reduced the number of services per conception (1.65 ± 0.10 vs. 2.08 ± 0.12; each P ≤ 0.01). The results indicate that strategic treatment with GnRH or PGF2α in week 5 pp to induce early ovulation and luteolysis reduces the incidence of COFs and PLP, respectively. Initial treatment with PGF2α also enhanced reproductive performance when used in conjunction with a standardized treatment protocol for all cows in week 8 pp (aimed at timely breeding). In contrast, GnRH did not improve fertility parameters of cystic cows in herds where all

Topics: Animals; Cattle; Cloprostenol; Corpus Luteum; Dairying; Dinoprost; Female; Fertility; Gonadotropin-Releasing Hormone; Incidence; Luteolysis; Ovarian Cysts; Ovarian Follicle; Postpartum Period; Pregnancy; Reproduction

This study was designed to examine estrous response rates to the therapeutic treatment of clinical anestrus in high producing dairy cows and to identify the factors that could affect these rates. Cows with silent ovulation (Subestrus group), cystic ovarian disease (Cyst group) or ovarian hypofunction (OH group) were given specific treatment for their disorder. Data were derived from 1764 treatments in cows producing a mean of 45.4 kg of milk upon treatment including: 889 subestrous cows, 367 cystic cows and 508 cows with ovarian hypofunction. Cows showing estrus following treatment exhibited a similar pregnancy rate to cows attaining natural estrus used as reference: 33% (337/1006) and 35% (626/1796), respectively. No significant differences in pregnancy rates were observed among the Subestrus, Cyst and OH groups (34% (196/571), 34% (44/130), 32% (97/305), respectively. Based on the odds ratio, an estrous response for all groups was less likely to occur in cows that had suffered previous anestrus, compared to cows that were anestrous for the first time, whereas the likelihood of an estrous response increased in cows treated after 90 days in milk. Our results indicate that previous anestrus and a late stage of lactation can have a negative and positive effect, respectively, on the estrous response to the specific treatment of clinical anestrus shown by high producing dairy cows. Treatment targeted at each type of clinical anestrus can render similar pregnancy rates to those shown by cows in natural estrus.

Topics: Anestrus; Animals; Cattle; Cattle Diseases; Cloprostenol; Dairying; Female; Fertility Agents, Female; Insemination, Artificial; Lactation; Ovarian Cysts; Ovarian Function Tests; Ovulation Induction; Progesterone

It was the aim of this field study to evaluate two different protocols of ovulation synchronization for the treatment of ovarian cysts and their effect on reproductive performance in dairy cows. In addition, factors with a possible influence on treatment success and pregnancy outcome as well as costs per pregnancy were analysed. The study was performed with 130 German Holsteins with ovarian cysts diagnosed on days 55 to 60 postpartum. Cows belonging to group 1 (n = 65) received a modified ovsynch protocol [day 0: 0.15 mg cloprostenol (PGF) + 0.02 mg buserelin acetate (GnRH); day 14: PGF; day 16: GnRH]. Group 2 (n = 65) was treated with the conventional ovsynch protocol (day 0: GnRH; day 7: PGF; day 9: GnRH). Timed artificial insemination was performed 20 to 24 h later. Cows without ovarian cysts served as controls. Treatment success (disappearance of the ovarian cyst) after the first ovsynch cycle was higher in group 1 (66.2%) than in group 2 (23.1%, p < 0.05). Reproductive measures in group 1 were comparable with those of the control group and, compared with group 2, were conspicuously better (66.2%, 76.9%, 83.1%, 59.5% vs. 40.0%, 50.7%, 60.0%, 27.5% for cumulative pregnancy rate after treatment cycle 1 to 3 and second service conception rate, respectively, p < 0.05). Overconditioned cows and cows with larger ovarian cysts showed a diminished treatment and pregnancy success. In group 1, costs per pregnancy were only slightly higher than in the control group (group 1: €352.44, group 2: €484.59, control group: €333.77). In conclusion, our results suggest that ovsynch protocols can be used in the treatment of ovarian cysts. The modified ovsynch protocol led to a better cure rate as well as a better reproductive performance, and was economically beneficial compared with a conventional ovsynch protocol.

Topics: Animals; Buserelin; Cattle; Cloprostenol; Female; Fertility Agents, Female; Insemination, Artificial; Lactation; Logistic Models; Ovarian Cysts; Ovulation Induction; Postpartum Period; Pregnancy; Pregnancy Rate; Reproduction

Cystic ovarian disease is an important cause of reproductive failure and economic loss for the dairy industry. This report describes two consecutive studies. The objective of the first was to evaluate the response of cows with ovarian cysts to two therapeutic treatments. In the second study, we compared the effectiveness of the best treatment established in Study 1 with that of the Ovsynch protocol. For Study 1, cows were considered to have an ovarian cyst if it was possible to observe a single follicular structure with a follicular antrum diameter > 25 min in the absence of a corpus luteum in three ultrasonographic examinations performed at 7 days intervals. At diagnosis (Day 0), cows were assigned to one of two treatment groups. Cows in Group GnRH/CLP (n = 31) were treated with 100 microg GnRH i.m. and 500 microg cloprostenol (CLP) i.m. on Day 14. Cows in Group GnRH-CLP/CLP(n = 32) were treated with 100 microg GnRH i.m. plus 500 microg CLP i.m. on Day 0, and 500 microg CLP i.m. on Day 14. The animals were inseminated at observed estrus and monitored weekly by ultrasonography for 4 weeks or until Al. Cows in the GnRH-CLP/CLP group showed a lower cystic persistence rate (15.6% < 45.2%; P = 0.01); a higher estrus detection rate (84.4% > 41.9%; P < 0.0001); a higher ovulation rate (75% versus 32.3%; P < 0.0001) and a higher early response rate (31% > 3%; P = 0.02) than those in the GnRH/CLP group. For the second study, 128 cows with ovarian cysts were randomly assigned to one of two treatment groups: cows in Group Ovsynch (n = 64) were treated with 100 microg GnRH i.m. on Day 0, 500 microg CLP on Day 7, and 100 microm GnRH i.m. 36 h later. Cows in this group were inseminated 24 h after the second GnRH dose (Ovsynch protocol). Cows in Group GnRH-CLP/CLP/GnRH (n = 64)were treated as those in the GnRH-CLP/CLP group of Study 1 but received GnRH 32 h after the second CLP treatment and were inseminated 24 h after this. A further group of cows without ovarian cysts inseminated at natural estrus served as the Group Control (n = 64). Cows in the GnRH-CLP/CLP/ GnRH group showed a lower cystic persistence rate (10.9% < 46.9%; P < 0.0001); higher ovulation rate (79.7% > 17.2%; P < 0.0001); higher return to estrus rate (34.3% > 12.5%; P < 0.01) and higher pregnancy rate (28.1% > 3.1%; P < 0.01) than those in Ovsynch; and a similar pregnancy rate (28.1% versus 35.9%) to Control cows. These findings indicate that lactating cows with ovarian cysts can be successfully synch

Topics: Animals; Cattle; Cattle Diseases; Cloprostenol; Dairying; Female; Gonadotropin-Releasing Hormone; Insemination, Artificial; Male; Ovarian Cysts; Ovulation Induction; Pregnancy; Progesterone; Random Allocation; Reproduction; Ultrasonography

The objectives of this study were to evaluate ovarian changes in cows with follicular ovarian cysts following treatment with either GnRH or saline. The parameters determined were the intervals from treatment to observation of a CL and from treatment to disappearance of the cyst, and the association between serum concentrations of LH, FSH and the LH/FSH ratio, before and after treatment, with the test intervals. Thirty-nine cows were identified as having follicular cysts. The GnRH treatment induced a significant increase in LH and the LH/FSH ratio. The gonadotropin response was not associated with the intervals from treatment to CL detection or to disappearance of the cyst. Survival curves for the intervals from treatment to CL detection and cyst disappearance indicate that treatment with GnRH or saline did not yield significantly different results for either parameter. The results question the efficacy of treating cystic ovarian disease with GnRH.

Topics: Animals; Cattle; Cattle Diseases; Cloprostenol; Female; Follicle Stimulating Hormone; Gonadotropin-Releasing Hormone; Luteinizing Hormone; Ovarian Cysts; Ovarian Follicle; Ultrasonography

This study assessed the value of ultrasonography in characterising bovine cystic ovaries and monitoring their responses to different treatments. Thirteen cows were diagnosed by ultrasonography as having luteinised ovarian cysts and seven were diagnosed as having follicular ovarian cysts. Six of the former were treated with prostaglandin, four with a progesterone intravaginal device (PRID) and three with gonadotrophin-releasing hormone (Gn-RH); five of the latter were treated with Gn-RH and two with a PRID. All the animals were re-examined by ultrasound and blood was collected for the measurement of plasma progesterone concentration at intervals until oestrus. The treatment of the luteinised cysts with prostaglandin caused marked decreases in size and plasma progesterone concentration and altered their echotexture within two to four days; oestrus occurred within three to four days. In two of the cows treated with a PRID the cysts regressed within one to two weeks but the other two cows required supplementary treatment with prostaglandin; oestrus and ovulation were observed only after the cysts collapsed. Gn-RH stimulated oestrus and ovulation within three to four days but the cysts did not collapse until much later. The treatment of the follicular cysts with Gn-RH or a PRID caused fresh ovulation and the formation of a corpus luteum but had little immediate effect upon the cyst. The plasma progesterone concentrations in some of the cows with either follicular or luteal cysts were similar on the day of treatment and were therefore of little value in differentiating the types of cyst.(ABSTRACT TRUNCATED AT 250 WORDS)

Topics: Administration, Intravaginal; Animals; Cattle; Cattle Diseases; Cloprostenol; Corpus Luteum; Dinoprost; Estrus; Female; Gonadotropin-Releasing Hormone; Injections, Intramuscular; Ovarian Cysts; Ovulation; Pregnancy; Progesterone; Prostaglandins F; Radioimmunoassay; Ultrasonography

The luteinising hormone (LH) surge in response to 1 mg oestradiol benzoate intramuscular injection was studied on 67 occasions in 45 cows with cystic ovarian disease 20 to 150 days post partum. Cows diagnosed as having luteal cysts were given 500 micrograms cloprostenol intramuscularly 24 hours before oestradiol, to induce luteolysis. Oestradiol benzoate was also given to eight post partum acyclic and eight cyclic cows and in all these cases a control LH response was characterised for comparison. Eight of 17 cows with luteal cysts (47 per cent), and 10 of 21 cows with follicular cysts (48 per cent), released LH in response to oestradiol. Some cows with cysts were given one of two treatments. Seven cows with follicular cysts were treated with a progesterone-releasing device (PRID) for seven days: all responded to a second oestradiol treatment given 24 hours after removal of the PRID. Luteal cysts in three cows and follicular cysts in nine cows were ruptured manually: only one cow (a luteal case) responded to the second oestradiol treatment given 24 hours after manual rupture. In eight cows initially diagnosed with luteal cysts, cloprostenol was not given and plasma progesterone concentration at the time of oestradiol treatment was high (over 0.9 ng ml-1): none released LH in response to oestradiol. As manual rupture did not improve the LH response to oestradiol, it is concluded that the defective LH response to oestradiol in cows with cystic ovarian disease was not influenced in the short-term by cyst fluid contents.(ABSTRACT TRUNCATED AT 250 WORDS)

Topics: Animals; Cattle; Cattle Diseases; Cloprostenol; Delayed-Action Preparations; Estradiol; Female; Injections, Intramuscular; Luteinizing Hormone; Ovarian Cysts; Progesterone

Cystic ovarian disease in cows was treated either with a single intramuscular injection of 500 micrograms cloprostenol, a prostaglandin F2 alpha analogue, in 77 cases of luteal cysts or with 500 micrograms gonadorelin or 20 micrograms buserelin, gonadotrophin releasing hormone or its analogue (GnRH), in 116 cases of follicular cysts. Recovery was defined as the absence of cysts and the formation of a corpus luteum either with or without observed oestrus within 10 days after treatment with cloprostenol and 15 days after treatment with GnRH. Recovery occurred in 65 per cent and 52.6 per cent of cases, respectively, in average times of 4.9 and 19 days. Fifteen days after treatment with GnRH, 20 cows with luteinised cysts were treated with cloprostenol and 15 recovered in a mean of 20.4 days, while 10 which still had follicular cysts, were given GnRH and one recovered 31 days after the beginning of treatment. Another 27 cows, in which cysts became luteinised, were treated with cloprostenol seven days after treatment with GnRH to give quicker (average 11.5 days) but poor (48 per cent) recovery and with a higher rate (33 per cent) of recurrence of cysts. A progesterone releasing intrauterine device was used in 25 cases of cystic ovarian disease, some of which had been previously treated. Sixty-eight per cent recovered in an average of 15 days. The proportions of cows becoming pregnant to one to three inseminations after the different methods of treatment were similar (77 to 94 per cent).(ABSTRACT TRUNCATED AT 250 WORDS)

Topics: Animals; Buserelin; Cattle; Cattle Diseases; Cloprostenol; Drug Evaluation; Estradiol; Female; Gonadotropin-Releasing Hormone; Hormones; Ovarian Cysts; Progesterone; Prostaglandins F, Synthetic

Path analysis was used to determine the interrelationships between postpartum administration of gonadotrophin releasing hormone and cloprostenol and the occurrence of reproductive disease and reproductive performance in dairy cows. The data analysed were those collected on 226 Holstein-Friesian cows calving in a commercial dairy herd during a 17 month period (May 1, 1981 to October 1, 1982). Cows administered gonadotrophin releasing hormone at day 15 postpartum experienced an improved rate of uterine involution as determined by rectal palpation nine days later. Although this improved rate of uterine involution reduced the risk of pyometritis, it actually directly delayed conception. Also, gonadotrophin releasing hormone therapy directly resulted in an increased incidence of pyometritis which in turn resulted in an increase incidence of cystic ovarian disease and anestrus. The occurrence of these abnormalities resulted in increased intervals from calving to first observed estrus, first service and conception. In addition to this effect, the administration of gonadotrophin releasing hormone was also associated with increased plasma progesterone concentrations at days 24 and 28 postpartum which delayed conception. Cloprostenol therapy at day 24 postpartum resulted in a decreased plasma progesterone concentration at day 28 postpartum which was directly and indirectly associated with a decrease in the calving to conception interval. The indirect effects were mediated by a reduction in days to first estrus. Cloprostenol therapy also directly resulted in a decreased calving to first observed estrus interval for reasons not attributable to the level of progesterone at day 28.

Topics: Anestrus; Animals; Cattle; Cattle Diseases; Cloprostenol; Endometritis; Estrus; Female; Insemination; Models, Biological; Ovarian Cysts; Pituitary Hormone-Releasing Hormones; Pregnancy; Progesterone; Puerperal Disorders; Reproduction; Suppuration

Topics: Animals; Cattle; Cattle Diseases; Cloprostenol; Female; Fertility; Gonadotropin-Releasing Hormone; Hormones; Milk; Ovarian Cysts; Progesterone; Prostaglandins F, Synthetic